Designing the magic bullet? the advancement of immuno-PET into clinical use

Journal of Nuclear Medicine

Volumn 54, Issue 8, 2013, Pages 1171-1174

  Wright, Brian D ^a   Lapi, Suzanne E ^a  

^a WASHINGTON UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

124I; 89Zr; Immuno PET; PET; Positron

Indexed keywords

BEVACIZUMAB ZR 89; CETUXIMAB ZR 89; COPPER 64; DEFEROXAMINE MESYLATE; EPIDERMAL GROWTH FACTOR RECEPTOR 2; GALLIUM 68; GIRENTUXIMAB I 124; GIRENTUXIMAB ZR 89; IODINE 124; MONOCLONAL ANTIBODY; MONOCLONAL ANTIBODY A33 I 124; PANITUMUMAB ZR 89; PHOSPHATIDYLINOSITOL 3 KINASE; PROTEIN KINASE B; RADIOISOTOPE; RADRETUMAB I 131; TECHNETIUM 99M; TRACER; TRASTUZUMAB; TRASTUZUMAB CU 64; TRASTUZUMAB ZR 89; U 3 1287 CU 64; U 36 ZR 89; UNCLASSIFIED DRUG; YTTRIUM 86; ZIRCONIUM 89;

ABSENCE OF SIDE EFFECTS; ARTICLE; BRAIN METASTASIS; BREAST CANCER; COLON ADENOCARCINOMA; COLORECTAL CANCER; COMPUTER ASSISTED EMISSION TOMOGRAPHY; COMPUTER ASSISTED TOMOGRAPHY; DIAGNOSTIC ACCURACY; DIAGNOSTIC VALUE; DRUG CLEARANCE; DRUG DISTRIBUTION; DRUG HALF LIFE; DRUG HYPERSENSITIVITY; DRUG INDUCED HEADACHE; DRUG LIVER LEVEL; DRUG RETENTION; DRUG SAFETY; DRUG TARGETING; DRUG UPTAKE; ENZYME INACTIVATION; HEAD AND NECK SQUAMOUS CELL CARCINOMA; HUMAN; IMMUNO POSITRON EMISSION TOMOGRAPHY; ISOTOPE LABELING; KIDNEY CARCINOMA; LIVER METASTASIS; NONHUMAN; OPTIMAL DRUG DOSE; POSITRON EMISSION TOMOGRAPHY; PRIORITY JOURNAL; PROTEIN EXPRESSION; RADIOIODINATION; SENSITIVITY AND SPECIFICITY; SIDE EFFECT; TISSUE DISTRIBUTION; UNSPECIFIED SIDE EFFECT;

124I; 89ZR; IMMUNO-PET; PET; POSITRON;

ANTIBODIES, MONOCLONAL; HUMANS; IODINE RADIOISOTOPES; ISOTOPE LABELING; POSITRON-EMISSION TOMOGRAPHY; ZIRCONIUM;

EID: 84881426703     PISSN: 01615505     EISSN: None     Source Type: Journal    
DOI: 10.2967/jnumed.113.126086     Document Type: Article

References (24)

1. Ehrlich C. Experimental Researches on Specific Therapy: On Immunity with Special Reference to the Relationship Between Distribution and Action of Antigens. Royal Institute of Public Health. 107th ed. London, U.K.: Lewis; 1908.
2. Scolnik PA. mAbs: a business perspective. MAbs. 2009;1:179-184.
3. van Dongen GAMS, Vosjan MJWD. Immuno-positron emission tomography: shedding light on clinical antibody therapy. Cancer Biother Radiopharm. 2010;25:375-385.
4. Mortimer JE. National Cancer Institute at the National Institutes of Health. Positron emission tomography in women with advanced HER2-positive breast cancer. http://www.cancer.gov/clinicaltrials/search/view? cdrid5669649&version5HealthProfessional&protocolsearchid511815781. Accessed July 9, 2013.
5. Wadas TJ, Wong EH, Weisman GR, Anderson CJ. Coordinating radiometals of copper, gallium, indium, yttrium and zirconium for PET and SPECT imaging of disease. Chem Rev. 2010;110:2858-2902.
6. Ruggiero A, Holland JP, Lewis JS, Grimm J. Cerenkov luminescence imaging of medical isotopes. J Nucl Med. 2010;51:1123-1130.
7. Verel I, Visser GWM, Boerman OC, et al. Long-lived positron emitters zirconium-89 and iodine-124 for scouting of therapeutic radioimmunoconjugates with PET. Cancer Biother Radiopharm. 2003;18:655-661.
8. Knowles SM, Wu AM. Advances in immuno-positron emission tomography: antibodies for molecular imaging in oncology. J Clin Oncol. 2012;30:3884-3892.
9. Koehler L, Gagnon K, McQuarrie S, Wuest F. Iodine-124: a promising positron emitter for organic PET chemistry. Molecules. 2010;15:2686-2718.
10. Deri MA, Zeglis BM, Francesconi LC, Lewis JS. PET imaging with 89Zr: from radiochemistry to the clinic. Nucl Med Biol. 2013;40:3-14.
11. Fraker PJ, Speck JC. Protein and cell membrane iodinations with a sparingly soluble chloroamide, 1,3,4,6-tetrachloro-3a, 6a-diphenylglycoluril. Biochem Biophys Res Commun. 1978;80:849-857.
12. Verel I, Visser GWM, Boellaard R, Walsum MS, Snow GB, van Dongen GAMS. 89Zr immuno-PET: comprehensive procedures for the production of 89Zr-labeled monoclonal antibodies. J Nucl Med. 2003;44:1271-1281.
13. Vosjan MJWD, Perk LR, Visser GWM, et al. Conjugation and radiolabeling of monoclonal antibodies with zirconium-89 for PET imaging using the bifunctional chelate p-isothiocyanatobenzyl-desferrioxamine. Nat Protoc. 2010;5:739-743.
14. 124I-huA33 antibody PET of colorectal cancer. J Nucl Med. 2011;52:1173-1180.
15. 124I-L19SIP dosimetric PET study. Cancer Immunol Res. 2013:OF1-OF10.
16. Schliemann C, Neri D. Antibody-based vascular tumor targeting. Recent Results Cancer Res. 2010;180:201-216.
17. Divgi CR, Uzzo RG, Gatsonis C, et al. Positron emission tomography/computed tomography identification of clear cell renal cell carcinoma: results from the REDECT Trial. J Clin Oncol. 2013;31:187-194.
18. 124I-and 89Zr-labeled anti-CAIX monoclonal antibody cG250 in mice. Cancer Biother Radiopharm. May 22, 2013 [Epub ahead of print].
19. Lurje G, Lenz HJ. EGFR signaling and drug discovery. Oncology. 2009;77: 400-410.
20. Nayak TK, Garmestani K, Mielenic DE, Brechbiel MW. PET and MR imaging of metastatic peritoneal and pulmonary colorectal cancer in mice with human epidermal growth factor receptor 1-targeted 89Zr-Labeled panitumumab. J Nucl Med. 2012;53:113-120.
21. Chang AJ, DeSilva RA, Lapi SE. Development and characterization of 89Zrlabeled panitumumab for immuno-positron emission tomographic imaging of the epidermal growth factor receptor. Mol Imaging. 2013;12:17-27.
22. Börjesson PKE, Jauw YWS, de Bree R, et al. Radiation dosimetry of 89Zrlabeled chimeric monoclonal antibody U36 as used for immuno-PET in head and neck cancer patients. J Nucl Med. 2009;50:1828-1836.
23. Dijkers EC, Oude Munnink TH, Kosterink JG, et al. Biodistribution of 89Zrtrastuzumab and PET imaging of HER2-positive lesions in patients with metastatic breast cancer. Clin Pharmacol Ther. 2010;87:586-592.
24. 89Zr. http://www.cancer.gov/clinicaltrials/search/results? protocolsearchid511815785. Accessed July 15, 2013.